Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADX-626
- Development stage
- Phase 1
- Lead developer
- ADARx Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ADX-626 is an investigational small interfering RNA (siRNA)-based therapeutic candidate developed to selectively and durably inhibit Factor XI, a key component in the intrinsic pathway of the coagulation cascade. By targeting Factor XI, ADX-626 aims to provide effective prevention of thrombosis while minimizing bleeding complications. It is being developed for thrombotic diseases such as deep venous thrombosis, atrial fibrillation, stroke, and acute coronary syndrome. The drug is designed for liver delivery and is currently undergoing Phase 1 clinical trials to evaluate its safety and pharmacodynamic activity[1][2].
02
Targets
F11 (Coagulation Factor XI)
Beyond the preview
Go deeper on ADX-626.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADX-626.